Prof Eliza Hawkes
LightNews LightNews
banner
elizahawkes.bsky.social
Prof Eliza Hawkes
@elizahawkes.bsky.social
160 followers 150 following 21 posts
Chief Clinical Research Officer & Lymphoma Clinical Innovations Lab head
At Olivia Newton John Cancer Research Institute.

Lymphoma Lead
At ONJCancerCentre
Lymphoma Researcher Monash University
#lymsm #hemesky #medsky
Views are my own
Posts Replies Media Videos
Reposted by Prof Eliza Hawkes
lymphomahub.bsky.social
During our latest steering committee meeting, Gareth Gregory chaired a discussion on Glofit-GemOx in patients with R/R DLBCL.

Learn more: https://loom.ly/YpxZNZM

#lymphoma #lymsm #MedEd #MedNews
November 25, 2025 at 9:01 AM
Reposted by Prof Eliza Hawkes
womeninlymphoma.bsky.social
We are excited to launch our new initiative - Women in Lymphoma Academy CAR-T Educational Internship. Applications are invited for a 2 week internship commencing August 2026 in Singapore. Eligibility criteria and application information can be found at womeninlymphoma.org/wil-academy
November 13, 2025 at 6:02 AM
elizahawkes.bsky.social
Dr Zoe Loh kicked off her PhD with this review of newer MCL biomarkers in the era of targeted therapies. Great expert input also from Dr Paul yeh and A/Prof Colm Keane. @onjcri.org.au

haematologica.org/haematologic...
Early View | Haematologica
haematologica.org
November 11, 2025 at 10:20 PM
elizahawkes.bsky.social
Our fantastic @onjcri.org.au and @lardr.bsky.social teams presenting lymphoma research orals at #HSANZ Blood conference in Perth. Dr Liz Goodall, Dr Allison barraclough, Eliza Chung and Rebecca nightingale and Dr Arina Martynchyk. All rising @womeninlymphoma.bsky.social
October 30, 2025 at 12:00 PM
Reposted by Prof Eliza Hawkes
womeninlymphoma.bsky.social
Our next webinar series on MCL starts on Oct 29th with Dr Maria Gomes da Silva, Dr Christine Ryan, Dr Clémentine Sarkozy and Dr Ann LaCasce
Register ➡️ us06web.zoom.us/webinar/regi...
October 16, 2025 at 9:21 PM
Reposted by Prof Eliza Hawkes
womeninlymphoma.bsky.social
WiLing Wednesday's Webinars are back! Join us for updates on various MCL topics presented by global experts, starting Oct 29 through to Nov 19.
Register on our website : womeninlymphoma.org/webinars
First session on Oct 29 : us06web.zoom.us/webinar/regi...
September 23, 2025 at 11:31 PM
elizahawkes.bsky.social
Thanks to Dr Yamshon and @johnpleonardmd.bsky.social for your excellent editorial:
Unstacking the deck in follicular lymphoma clinical trials url: academic.oup.com/jnci/article...

In response to our paper here:

academic.oup.com/jnci/article...
Unstacking the deck in follicular lymphoma clinical trials
Treating follicular lymphoma is a marathon, not a sprint. From the moment of diagnosis, patients must carefully balance short-term efficacy and toxicity wi
academic.oup.com
September 19, 2025 at 9:35 AM
elizahawkes.bsky.social
T‐Cell Receptor Repertoires Show Dynamic Variation Between Diagnosis and Relapse of Diffuse Large B‐Cell Lymphoma - Wight - 2025 - eJHaem - Wiley Online Library onlinelibrary.wiley.com/doi/10.1002/...
T‐Cell Receptor Repertoires Show Dynamic Variation Between Diagnosis and Relapse of Diffuse Large B‐Cell Lymphoma
Background Tumour infiltrating lymphocyte (TIL) T-cell receptor (TCR) repertoire is prognostic in newly diagnosed diffuse large B-cell lymphoma (DLBCL), but evolution has not been evaluated at relap.....
onlinelibrary.wiley.com
July 18, 2025 at 11:25 AM
elizahawkes.bsky.social
Meeting trial eligibility in follicular lymphoma patients is associated with overall survival but not progression-free survival url: academic.oup.com/jnci/article...
Meeting trial eligibility in follicular lymphoma patients is associated with overall survival but not progression-free survival
AbstractBackground. Clinical trial eligibility criteria are necessary for safety and target population homogeneity; however, increasingly restrictive organ
academic.oup.com
July 18, 2025 at 11:22 AM
Reposted by Prof Eliza Hawkes
ericawood.bsky.social
Please join us on 1 August for the inaugural open meeting of the OPTIMAL CRE in improving immunoglobulin use!
www.optimalcre.org

We'll have updates on research projects underway, and lots of opportunities to join the discussion.
Registration details below.
Everyone is welcome, in person or online!
June 26, 2025 at 12:47 AM
elizahawkes.bsky.social
Our multidisciplinary study of RT + immunotherapy with CD8 PET as a biomarker of response in relapse B-NHL

ashpublications.org/bloodadvance...
T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a Phase I trial.
Key Points. Delivering radiotherapy to multiple disease sites in combination with immunotherapies such as PDL1 inhibitors is safe.T-cell dysregulation iden
ashpublications.org
June 23, 2025 at 9:34 PM
Reposted by Prof Eliza Hawkes
lardr.bsky.social
Thanks to all who stopped by to chat with us at our #FollicularLymphoma #EHA2025 poster 👋

@hemasphere-journal.bsky.social @ericawood.bsky.social @elizahawkes.bsky.social
#LymphomaResearch #ClinicalResearch #Registry
LaRDR at EHA conference 2025!
lardr.org
June 17, 2025 at 7:18 AM
Reposted by Prof Eliza Hawkes
lardr.bsky.social
We're also showcasing our #18ICML posters:
-221, real-world data on end-of-treatment imaging #TCellLymphoma;
-390, Ki67 expression level in #FollicularLymphoma

See you June 18👋

@icmlugano.bsky.social @ericawood.bsky.social @elizahawkes.bsky.social
#LymphomaResearch #ClinicalResearch #Registry
END‐OF‐TREATMENT PET/CT COMPLETE REMISSION IS HIGHLY PROGNOSTIC IN NODAL PERIPHERAL T‐CELL LYMPHOMA: AN AUSTRALASIAN‐CANADIAN COLLABORATIVE STUDY
Click on the article title to read more.
doi.org
June 18, 2025 at 2:48 AM
Reposted by Prof Eliza Hawkes
graham74gc.bsky.social
Stathis et al - feasibility of PET & ctDNA response adaptation in 1L DLBCL.
• operationally deliverable with ctDNA turnaround median 9d
• low rate PET+ and ctDNA+ at interim
• assessing whether acala addition benefits those with Myd88 &/or CD79b mutns
SAKK38/19 trial #ICML18
June 18, 2025 at 12:50 PM
Reposted by Prof Eliza Hawkes
majorajay.bsky.social
PROs from BRUIN-321 pirto vs idelaR/BR R/R CLL #18ICML
- pirto: better improvements in CLL-related sx, physical function, fatigue, all clinically significant
- 83% PRO completion pirto at week 25, only 59% other arm
Grain of salt given PRO dropout, but well reported. #lymsm
June 18, 2025 at 7:12 PM
Reposted by Prof Eliza Hawkes
lardr.bsky.social
We're excited to meet you at our #EHA2025 poster PS1885 to talk about the study of Ki67 expression in Australasian #FollicularLymphoma patients.

See you Saturday, June 14 👋

@hemasphere-journal.bsky.social @ericawood.bsky.social @elizahawkes.bsky.social
#LymphomaResearch #ClinicalResearch #Registry
DETERMINING THE PROGNOSTIC SIGNIFICANCE OF THE KI67 PROLIFERATION... by Eliza Chung
EHA Library; Chung E. Jun 14 2025; 4160959;
library.ehaweb.org
June 12, 2025 at 5:01 AM
Reposted by Prof Eliza Hawkes
womeninlymphoma.bsky.social
Join us now at our poster in #ASCO2025 to discuss gender demographics and equity in professional opportunities!
June 1, 2025 at 4:02 PM
elizahawkes.bsky.social
Pleased to work with my U.K. colleagues this analysis of PET data from our CHEMO-T study in PTCL led by #drgleeson and #drchua

onlinelibrary.wiley.com/doi/10.1111/...
The role of PET/CT in peripheral T‐cell lymphoma: Results from the PET/CT substudy of the UK NCRI phase 2 CHEMO‐T trial
A PET/CT substudy of the UK NCRI CHEMO-T phase 2 trial was performed to further investigate the role of PET/CT in previously untreated patients with peripheral T-cell lymphoma (N = 82). Our findings ...
onlinelibrary.wiley.com
May 27, 2025 at 9:40 PM
Reposted by Prof Eliza Hawkes
lardr.bsky.social
The Lymphoma and Related Diseases Registry enrolled the ⭐9000th⭐ participant on May 8, 2025!

We would like to express our sincere gratitude to all participants, participating sites and staff, principal investigators and industry partners for their continued support of the registry 🙌
May 8, 2025 at 12:40 AM
elizahawkes.bsky.social
Our study showing 3D volume assessment of PCNSL on MRI is more accurate than standard criteria in response assessment and prognostication. academic.oup.com/noa/advance-...
Refinement of primary central nervous system lymphoma prognostication and response assessment using 3-Dimensional MRI
AbstractBackground. Primary central nervous system lymphoma (PCNSL) is an aggressive lymphoma restricted to the CNS in which outcomes cannot be reliably pr
academic.oup.com
May 6, 2025 at 8:29 PM
Reposted by Prof Eliza Hawkes
womeninlymphoma.bsky.social
Join us tomorrow for last webinar of this series "Careers in Pharma" with Dr Connie Batlevi & Jamie Hirata along with Casulo Carla & Judith Trotman
Register at us06web.zoom.us/webinar/regi...
May 6, 2025 at 10:13 AM
Reposted by Prof Eliza Hawkes
icmlugano.bsky.social
📢 We are excited to announce that the #18ICML Scientific Programme IS ONLINE: shorturl.at/FlsmC

Thank you to our international Advisory Board and reviewers for their precious help!
April 30, 2025 at 3:33 PM
Reposted by Prof Eliza Hawkes
womeninlymphoma.bsky.social
Don't miss the last webinar of this series next week with Connie Batlevi & Jamie Hirata presenting on Careers in Pharma along with Casulo Carla & @judithtrotman.bsky.social !
Register at us06web.zoom.us/webinar/regi...
May 2, 2025 at 8:43 AM
Reposted by Prof Eliza Hawkes
bloodjournals.hematology.org
Emerging biomarkers for CD3×CD20 bispecific antibodies in lymphoma
buff.ly/2sCOERm #hemesky #bloodspotlight #lymphoidneoplasia
April 30, 2025 at 8:02 PM
Reposted by Prof Eliza Hawkes
lardr.bsky.social
LaRDR supports early-career clinician-researchers by providing #research opportunities📊. They gain experience in manuscript writing ✍️ for publication and conference presentations.

Tune in to this interview to hear more from Dr Wang!
🎬 youtu.be/0rjytiYHhuY
LaRDR Interview - Research experience from basic physician to haematology registrar
YouTube video by Transfusion Research Unit
youtu.be
May 1, 2025 at 5:32 AM